In CommitteeFiled Jul 22, 2026
Sponsor: Rep. Auchincloss, Jake [D-MA-4] (D)
Latest Action
Referred to the House Committee on Energy and Commerce.
Jul 22, 2026
Summary
The bill amends federal health laws to make Alzheimer’s biomarker testing a covered benefit for people with group health plans, private insurance, and Medicaid. It affects patients at risk for Alzheimer’s, health insurers, and the Medicaid program. The goal is to improve early detection and treatment options.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Track this bill
Get real-time alerts when HR 9823 changes status, plus AI-powered summaries and stage predictions.
Sign up free